Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28744136
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Vasc+Health+Risk+Manag
2017 ; 13
(ä): 263-267
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Quick reference guide to apixaban
#MMPMID28744136
Hurst KV
; O'Callaghan JM
; Handa A
Vasc Health Risk Manag
2017[]; 13
(ä): 263-267
PMID28744136
show ga
Direct oral anticoagulants (DOACs) are being increasingly used in the clinical
setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These
medications offer valued benefits for long-term use, including a fast onset of
anticoagulation, fixed anticoagulation profile (and consequent prescription of
specified doses) and no requirement for routine monitoring. Apixaban is a
selective factor Xa inhibitor, approved for use in the prevention of stroke in
patients with nonvalvular atrial fibrillation and in the prevention and treatment
of acute VTE. Like many of the DOACs, it has a fast onset of action and works to
deliver predictable coagulation results. Multiple randomized controlled trials
including ARISTOTLE and AMPLIFY have shown apixaban to be noninferior to vitamin
K antagonists in the prevention of stroke and VTE, with a good safety profile.
This article aims to review the use of apixaban for the prevention and treatment
of thromboembolic disease, highlighting the key study results that have led to
its current licensing and use.
|Administration, Oral
[MESH]
|Blood Coagulation/*drug effects
[MESH]
|Factor Xa Inhibitors/*administration & dosage/adverse effects/pharmacokinetics
[MESH]
free
free
free
